Image by Getty / Futurism A Swiss pharmaceutical company hoping to cash in on the weight loss drug trend is having its dreams dashed amid new results showing that the drugs cause a broad majority of patients to yak. As the Financial Times reports, the drugmaker Roche found in trials for the experimental drug, dubbed CT-388, that a majority of people who took the highest dose of it in both injectable and pill form suffered from nausea and vomiting. Revealed during the annual meeting of the European Association for the Study of Diabetes last week, these new side effect results found that a whopping 75 percent of those who take the highest dose of the injectable version of the as-yet-unbranded drug experienced vomiting. Results for the pill version, which Roche acquired along with injectable CT-388 when it purchased Carmot Therapeutics at the beginning of this year, were similar. Trying to quell investor concerns that saw its stock fall five percent in the wake of the trial results, a Roche representative suggested that the side effects were …